Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Overview[ - collapse ][ - ]

Purpose This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM). Study will compare four dose combinations of empagliflozin + metformin versus each individual component after 24 weeks of treatment.
ConditionDiabetes Mellitus, Type 2
Hyperglycemia
InterventionDrug: Empagliflozin low dose qd
Drug: Metformin 500 mg bid
Drug: Metformin 1000 mg bid
Drug: Empagliflozin high dose qd
Drug: Empagliflozin low dose bid
Drug: Metformin 500 mg bid
Drug: Empagliflozin high dose bid
Drug: Empagliflozin low dose bid
Drug: Metformin 1000 mg bid
Drug: Metformin 500 mg bid
Drug: Metformin 1000 mg bid
Drug: Empagliflozin high dose bid
Drug: Metformin 1000 mg bid
Drug: Empagliflozin high dose bid
PhasePhase 3
SponsorBoehringer Ingelheim
Responsible PartyBoehringer Ingelheim
ClinicalTrials.gov IdentifierNCT01719003
First ReceivedOctober 30, 2012
Last UpdatedApril 16, 2014
Last verifiedApril 2014

Tracking Information[ + expand ][ + ]

First Received DateOctober 30, 2012
Last Updated DateApril 16, 2014
Start DateOctober 2012
Estimated Primary Completion DateNovember 2014
Current Primary Outcome MeasuresChange from baseline in HbA1c [Time Frame: 24 weeks] [Designated as safety issue: No]
Current Secondary Outcome Measures
  • Change from baseline in fasting plasma glucose (FPG) [Time Frame: 24 weeks] [Designated as safety issue: No]
  • Change from baseline in body weight [Time Frame: 24 weeks] [Designated as safety issue: No]

Descriptive Information[ + expand ][ + ]

Brief TitleSafety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Official TitleA 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Brief Summary
This study will investigate the efficacy and safety of two doses (high and low) of
empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in
patients with type 2 diabetes mellitus (T2DM). Study will compare four dose combinations of
empagliflozin + metformin versus each individual component after 24 weeks of treatment.
Detailed DescriptionNot Provided
Study TypeInterventional
Study PhasePhase 3
Study DesignAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Condition
  • Diabetes Mellitus, Type 2
  • Hyperglycemia
InterventionDrug: Empagliflozin low dose qd
Empagliflozin low dose once daily
Drug: Metformin 500 mg bid
Metformin 500 mg twice daily
Drug: Metformin 1000 mg bid
Metformin 1000 mg twice daily
Drug: Empagliflozin high dose qd
Empagliflozin high dose once daily
Drug: Empagliflozin low dose bid
Empagliflozin low dose split twice daily
Drug: Metformin 500 mg bid
Metformin 500 mg twice daily
Drug: Empagliflozin high dose bid
Empagliflozin high dose split twice daily
Drug: Empagliflozin low dose bid
Empagliflozin low dose split twice daily
Drug: Metformin 1000 mg bid
Metformin 1000 mg twice daily
Drug: Metformin 500 mg bid
Metformin 500 mg twice daily
Drug: Metformin 1000 mg bid
Metformin 1000 mg twice daily
Drug: Empagliflozin high dose bid
Empagliflozin high dose split twice daily
Drug: Metformin 1000 mg bid
Metformin 1000 mg twice daily
Drug: Empagliflozin high dose bid
Empagliflozin high dose split twice daily
Study Arm (s)
  • Experimental: Empagliflozin low dose qd
    Empagliflozin low dose once daily
  • Experimental: Empagliflozin high dose qd
    Empagliflozin high dose once daily
  • Experimental: OL empa high dose + met 1000 mg bid
    Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
  • Experimental: Empagliflozin low dose + met 500 mg bid
    Empagliflozin low dose split twice daily + metformin 500 mg twice daily
  • Experimental: Empagliflozin low dose + met 1000 mg bid
    Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
  • Experimental: Empagliflozin high dose + met 500 mg bid
    Empagliflozin high dose split twice daily + metformin 500 mg twice daily
  • Experimental: Empagliflozin high dose + met 1000mg bid
    Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
  • Experimental: Metformin 500 mg bid
    Metformin 500 mg twice daily
  • Experimental: Metformin 1000 mg bid
    Metformin 1000 mg twice daily

Recruitment Information[ + expand ][ + ]

Recruitment StatusRecruiting
Estimated Enrollment1397
Estimated Completion DateNovember 2014
Estimated Primary Completion DateNovember 2014
Eligibility Criteria
Inclusion criteria:

1. Diagnosis of type 2 diabetes mellitus prior to informed consent

2. Male and female patients on diet and exercise regimen who are drug-naive, defined as
absence of any oral antidiabetic therapy for 12 weeks prior to randomization

3. HbA1c >=7.5% and <= 12% (>=58.5 mmol/mol and <=107.7 mmol/mol)

4. Body Mass Index (BMI) <= 45 kg/m2 at screening

Exclusion criteria:

1. Uncontrolled hyperglycemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an
overnight fast during placebo run-in and confirmed by a second laboratory measurement
(not on the same day)

2. Any antidiabetic drug within 12 weeks prior to randomization

3. Impaired renal function, defined as estimated creatinine clearance rate (eCCr) <60
ml/min (Cockcroft-Gault formula) as determined during screening and/or run-in period

4. Contraindications to metformin according to the local label
GenderBoth
Ages18 Years
Accepts Healthy VolunteersNo
ContactsContact: Boehringer Ingelheim Call Center
1-800-243-0127
clintriage.rdg@boehringer-ingelheim.com
Location CountriesUnited States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom

Administrative Information[ + expand ][ + ]

NCT Number NCT01719003
Other Study ID Numbers1276.1
Has Data Monitoring CommitteeNot Provided
Information Provided ByBoehringer Ingelheim
Study SponsorBoehringer Ingelheim
CollaboratorsEli Lilly and Company
Investigators Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Verification DateApril 2014

Locations[ + expand ][ + ]

1276.1.10014 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
Recruiting
1276.1.10019 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
Recruiting
1276.1.10044 Boehringer Ingelheim Investigational Site
Hot Springs, Alaska, United States
Recruiting
1276.1.10010 Boehringer Ingelheim Investigational Site
Glendale, Arizona, United States
Recruiting
1276.1.10035 Boehringer Ingelheim Investigational Site
Searcy, Arkansas, United States
Recruiting
1276.1.10046 Boehringer Ingelheim Investigational Site
Chula Vista, California, United States
Recruiting
1276.1.10006 Boehringer Ingelheim Investigational Site
Huntington Beach, California, United States
Recruiting
1276.1.10043 Boehringer Ingelheim Investigational Site
La Mesa, California, United States
Recruiting
1276.1.10040 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
Recruiting
1276.1.10009 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
Recruiting
1276.1.10045 Boehringer Ingelheim Investigational Site
Oceanside, California, United States
Recruiting
1276.1.10042 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
Recruiting
1276.1.10001 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
Recruiting
1276.1.10003 Boehringer Ingelheim Investigational Site
Northglenn, Colorado, United States
Recruiting
1276.1.10039 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
Recruiting
1276.1.10026 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
Recruiting
1276.1.10024 Boehringer Ingelheim Investigational Site
Oldsmar, Florida, United States
Recruiting
1276.1.10027 Boehringer Ingelheim Investigational Site
Port Orange, Florida, United States
Recruiting
1276.1.10023 Boehringer Ingelheim Investigational Site
Marietta, Georgia, United States
Recruiting
1276.1.10034 Boehringer Ingelheim Investigational Site
Evansville, Indiana, United States
Recruiting
1276.1.10032 Boehringer Ingelheim Investigational Site
Fall River, Massachusetts, United States
Recruiting
1276.1.10036 Boehringer Ingelheim Investigational Site
Bridgman, Michigan, United States
Recruiting
1276.1.10037 Boehringer Ingelheim Investigational Site
Hazelwood, Missouri, United States
Recruiting
1276.1.10007 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
Recruiting
1276.1.10015 Boehringer Ingelheim Investigational Site
Union, New Jersey, United States
Recruiting
1276.1.10033 Boehringer Ingelheim Investigational Site
Asheboro, North Carolina, United States
Recruiting
1276.1.10022 Boehringer Ingelheim Investigational Site
Burlington, North Carolina, United States
Recruiting
1276.1.10002 Boehringer Ingelheim Investigational Site
Lenoir, North Carolina, United States
Recruiting
1276.1.10005 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
Recruiting
1276.1.10011 Boehringer Ingelheim Investigational Site
Gallipolis, Ohio, United States
Recruiting
1276.1.10030 Boehringer Ingelheim Investigational Site
Columbia, South Carolina, United States
Recruiting
1276.1.10008 Boehringer Ingelheim Investigational Site
Greer, South Carolina, United States
Recruiting
1276.1.10013 Boehringer Ingelheim Investigational Site
Hodges, South Carolina, United States
Recruiting
1276.1.10017 Boehringer Ingelheim Investigational Site
Humboldt, Tennessee, United States
Recruiting
1276.1.10018 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
Recruiting
1276.1.10025 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
Recruiting
1276.1.10028 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
Recruiting
1276.1.10016 Boehringer Ingelheim Investigational Site
Kingwood, Texas, United States
Completed
1276.1.10021 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
Recruiting
1276.1.10041 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
Recruiting
1276.1.10004 Boehringer Ingelheim Investigational Site
Manassas, Virginia, United States
Recruiting
1276.1.10012 Boehringer Ingelheim Investigational Site
Wenatchee, Washington, United States
Recruiting
1276.1.55008 Boehringer Ingelheim Investigational Site
Belém, Brazil
Recruiting
1276.1.55003 Boehringer Ingelheim Investigational Site
Brasilia, Brazil
Recruiting
1276.1.55007 Boehringer Ingelheim Investigational Site
Fortaleza, Brazil
Recruiting
1276.1.55006 Boehringer Ingelheim Investigational Site
Fortaleza, Brazil
Recruiting
1276.1.55009 Boehringer Ingelheim Investigational Site
Fortaleza, Brazil
Recruiting
1276.1.55004 Boehringer Ingelheim Investigational Site
Goiania, Brazil
Recruiting
1276.1.55002 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
Recruiting
1276.1.55001 Boehringer Ingelheim Investigational Site
Sao Paulo, Brazil
Recruiting
1276.1.20003 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia, Canada
Recruiting
1276.1.20012 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia, Canada
Recruiting
1276.1.20008 Boehringer Ingelheim Investigational Site
Victoria, British Columbia, Canada
Recruiting
1276.1.20004 Boehringer Ingelheim Investigational Site
Antigonish, Nova Scotia, Canada
Recruiting
1276.1.20005 Boehringer Ingelheim Investigational Site
Hawkesbury, Ontario, Canada
Recruiting
1276.1.20013 Boehringer Ingelheim Investigational Site
Sarnia, Ontario, Canada
Recruiting
1276.1.20011 Boehringer Ingelheim Investigational Site
Stayner, Ontario, Canada
Recruiting
1276.1.20010 Boehringer Ingelheim Investigational Site
Strathroy, Ontario, Canada
Recruiting
1276.1.20006 Boehringer Ingelheim Investigational Site
Thornhill, Ontario, Canada
Recruiting
1276.1.20009 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
Recruiting
1276.1.20007 Boehringer Ingelheim Investigational Site
Mirabel, Quebec, Canada
Recruiting
1276.1.20001 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
Recruiting
1276.1.20002 Boehringer Ingelheim Investigational Site
Quebec, Canada
Recruiting
1276.1.42002 Boehringer Ingelheim Investigational Site
Benatky nad Jizerou, Czech Republic
Recruiting
1276.1.42008 Boehringer Ingelheim Investigational Site
Olomouc, Czech Republic
Recruiting
1276.1.42007 Boehringer Ingelheim Investigational Site
Ostrava, Czech Republic
Recruiting
1276.1.42009 Boehringer Ingelheim Investigational Site
Plzen, Czech Republic
Recruiting
1276.1.42010 Boehringer Ingelheim Investigational Site
Praha 1, Czech Republic
Recruiting
1276.1.42004 Boehringer Ingelheim Investigational Site
Praha 10, Czech Republic
Recruiting
1276.1.42003 Boehringer Ingelheim Investigational Site
Praha 3, Czech Republic
Recruiting
1276.1.95001 Boehringer Ingelheim Investigational Site
Abbasia Cairo, Egypt, Egypt
Recruiting
1276.1.95003 Boehringer Ingelheim Investigational Site
Al Manial, Cairo, Egypt, Egypt
Recruiting
1276.1.95004 Boehringer Ingelheim Investigational Site
Alexandria, Egypt
Recruiting
1276.1.95005 Boehringer Ingelheim Investigational Site
Alexandria, Egypt
Recruiting
1276.1.95002 Boehringer Ingelheim Investigational Site
El Darasa Cairo Egypt, Egypt
Recruiting
1276.1.33004 Boehringer Ingelheim Investigational Site
Behren Les Forbach, France
Completed
1276.1.33012 Boehringer Ingelheim Investigational Site
Bersée, France
Recruiting
1276.1.33005 Boehringer Ingelheim Investigational Site
Cournonterral, France
Recruiting
1276.1.33007 Boehringer Ingelheim Investigational Site
Hautmont, France
Completed
1276.1.33013 Boehringer Ingelheim Investigational Site
Paris, France
Recruiting
1276.1.33001 Boehringer Ingelheim Investigational Site
Poitiers, France
Recruiting
1276.1.33003 Boehringer Ingelheim Investigational Site
Savonnières, France
Recruiting
1276.1.33006 Boehringer Ingelheim Investigational Site
St Genis des Fontaines, France
Recruiting
1276.1.33002 Boehringer Ingelheim Investigational Site
Thouars, France
Recruiting
1276.1.33011 Boehringer Ingelheim Investigational Site
Thun St amand, France
Recruiting
1276.1.33010 Boehringer Ingelheim Investigational Site
Tours, France
Recruiting
1276.1.33009 Boehringer Ingelheim Investigational Site
Vandome, France
Recruiting
1276.1.33008 Boehringer Ingelheim Investigational Site
Vieux Condé, France
Recruiting
1276.1.49005 Boehringer Ingelheim Investigational Site
Berlin, Germany
Recruiting
1276.1.49008 Boehringer Ingelheim Investigational Site
Celle, Germany
Recruiting
1276.1.49006 Boehringer Ingelheim Investigational Site
Dortmund, Germany
Recruiting
1276.1.49011 Boehringer Ingelheim Investigational Site
Dresden, Germany
Recruiting
1276.1.49003 Boehringer Ingelheim Investigational Site
Essen, Germany
Recruiting
1276.1.49007 Boehringer Ingelheim Investigational Site
Ingelheim, Germany
Terminated
1276.1.49014 Boehringer Ingelheim Investigational Site
Neuwied, Germany
Recruiting
1276.1.49004 Boehringer Ingelheim Investigational Site
Offenbach, Germany
Recruiting
1276.1.49002 Boehringer Ingelheim Investigational Site
Stuhr-Brinkum, Germany
Recruiting
1276.1.49012 Boehringer Ingelheim Investigational Site
Teuchern, Germany
Recruiting
1276.1.50002 Boehringer Ingelheim Investigational Site
Barbena Santa Rosa, Guatemala
Recruiting
1276.1.50003 Boehringer Ingelheim Investigational Site
Guatemala, Guatemala
Recruiting
1276.1.50005 Boehringer Ingelheim Investigational Site
Guatemala, Guatemala
Recruiting
1276.1.50006 Boehringer Ingelheim Investigational Site
Guatemala, Guatemala
Recruiting
1276.1.50001 Boehringer Ingelheim Investigational Site
Quetzaltenango, Guatemala
Recruiting
1276.1.82009 Boehringer Ingelheim Investigational Site
Busan, Korea, Republic of
Recruiting
1276.1.82006 Boehringer Ingelheim Investigational Site
Deagu, Korea, Republic of
Recruiting
1276.1.82010 Boehringer Ingelheim Investigational Site
Goyang, Korea, Republic of
Recruiting
1276.1.82001 Boehringer Ingelheim Investigational Site
Incheon, Korea, Republic of
Recruiting
1276.1.82005 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
Recruiting
1276.1.82008 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
Recruiting
1276.1.82004 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
Recruiting
1276.1.82002 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
Recruiting
1276.1.82007 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
Recruiting
1276.1.82003 Boehringer Ingelheim Investigational Site
Wonju, Korea, Republic of
Recruiting
1276.1.96001 Boehringer Ingelheim Investigational Site
Beirut, Lebanon
Recruiting
1276.1.96002 Boehringer Ingelheim Investigational Site
Chouf, Lebanon
Recruiting
1276.1.96003 Boehringer Ingelheim Investigational Site
Sidon, Lebanon
Recruiting
1276.1.96004 Boehringer Ingelheim Investigational Site
Sidon, Lebanon
Recruiting
1276.1.60002 Boehringer Ingelheim Investigational Site
Ipoh, Perak, Malaysia
Recruiting
1276.1.60001 Boehringer Ingelheim Investigational Site
Johor Bahru, Malaysia
Recruiting
1276.1.60003 Boehringer Ingelheim Investigational Site
Kubang Kerian, Malaysia
Recruiting
1276.1.52004 Boehringer Ingelheim Investigational Site
Aguascalientes, Mexico
Recruiting
1276.1.52007 Boehringer Ingelheim Investigational Site
Aguascalientes, Mexico
Recruiting
1276.1.52002 Boehringer Ingelheim Investigational Site
Ciudad de Mexico, Mexico
Recruiting
1276.1.52003 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
Recruiting
1276.1.52001 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
Recruiting
1276.1.52006 Boehringer Ingelheim Investigational Site
San Lucas tepetlcalco, Mexico
Recruiting
1276.1.52005 Boehringer Ingelheim Investigational Site
Zapopan, Mexico
Recruiting
1276.1.51001 Boehringer Ingelheim Investigational Site
Lima, Peru
Recruiting
1276.1.51002 Boehringer Ingelheim Investigational Site
Lima, Peru
Recruiting
1276.1.51003 Boehringer Ingelheim Investigational Site
Lima, Peru
Recruiting
1276.1.51004 Boehringer Ingelheim Investigational Site
Lima, Peru
Recruiting
1276.1.51005 Boehringer Ingelheim Investigational Site
Lima, Peru
Recruiting
1276.1.63009 Boehringer Ingelheim Investigational Site
Cebu City, Cebu, Philippines
Recruiting
1276.1.63002 Boehringer Ingelheim Investigational Site
Cebu City, Philippines, Philippines
Recruiting
1276.1.63004 Boehringer Ingelheim Investigational Site
Davao City, Philippines
Recruiting
1276.1.63003 Boehringer Ingelheim Investigational Site
Iloilo City, Philippines
Recruiting
1276.1.63006 Boehringer Ingelheim Investigational Site
Manila, Philippines
Recruiting
1276.1.63001 Boehringer Ingelheim Investigational Site
Marikina City, Philippines
Recruiting
1276.1.63005 Boehringer Ingelheim Investigational Site
Maybunga, Pasig City, Philippines
Recruiting
1276.1.63007 Boehringer Ingelheim Investigational Site
San Juan City, Philippines
Recruiting
1276.1.63008 Boehringer Ingelheim Investigational Site
Tarlac, Philippines
Recruiting
1276.1.70012 Boehringer Ingelheim Investigational Site
Barnaul, Russian Federation
Recruiting
1276.1.70011 Boehringer Ingelheim Investigational Site
Kemerovo, Russian Federation
Recruiting
1276.1.70018 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
Recruiting
1276.1.70015 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
Recruiting
1276.1.70016 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
Recruiting
1276.1.70007 Boehringer Ingelheim Investigational Site
Petrozavodsk, Russian Federation
Recruiting
1276.1.70009 Boehringer Ingelheim Investigational Site
Saratov, Russian Federation
Recruiting
1276.1.70010 Boehringer Ingelheim Investigational Site
Smolensk, Russian Federation
Recruiting
1276.1.70006 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
Recruiting
1276.1.70005 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
Recruiting
1276.1.70017 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
Recruiting
1276.1.70013 Boehringer Ingelheim Investigational Site
Yaroslavl, Russian Federation
Recruiting
1276.1.38105 Boehringer Ingelheim Investigational Site
Belgrade, Serbia
Recruiting
1276.1.38107 Boehringer Ingelheim Investigational Site
Belgrade, Serbia
Recruiting
1276.1.38106 Boehringer Ingelheim Investigational Site
Belgrade, Serbia
Recruiting
1276.1.38104 Boehringer Ingelheim Investigational Site
Belgrade, Serbia
Recruiting
1276.1.38103 Boehringer Ingelheim Investigational Site
Kragujevac, Serbia
Recruiting
1276.1.38101 Boehringer Ingelheim Investigational Site
Nis, Serbia
Recruiting
1276.1.38108 Boehringer Ingelheim Investigational Site
Novi Sad, Serbia
Recruiting
1276.1.38102 Boehringer Ingelheim Investigational Site
Zajecar, Serbia
Recruiting
1276.1.34048 Boehringer Ingelheim Investigational Site
Alicante, Spain
Recruiting
1276.1.34050 Boehringer Ingelheim Investigational Site
Alzira, Spain
Recruiting
1276.1.34028 Boehringer Ingelheim Investigational Site
Madrid, Spain
Recruiting
1276.1.34045 Boehringer Ingelheim Investigational Site
pozuelo de Alarcon, Spain
Recruiting
1276.1.34034 Boehringer Ingelheim Investigational Site
Sabadell (Barcelona), Spain
Recruiting
1276.1.34027 Boehringer Ingelheim Investigational Site
Salamanca, Spain
Recruiting
1276.1.34052 Boehringer Ingelheim Investigational Site
Tarragona, Spain
Recruiting
1276.1.34051 Boehringer Ingelheim Investigational Site
Zaragoza, Spain
Recruiting
1276.1.88005 Boehringer Ingelheim Investigational Site
Kaohsiung City,, Taiwan
Recruiting
1276.1.88002 Boehringer Ingelheim Investigational Site
New Taipei City, Taiwan
Recruiting
1276.1.88004 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
Recruiting
1276.1.88001 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
Recruiting
1276.1.88003 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
Recruiting
1276.1.88006 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
Recruiting
1276.1.66001 Boehringer Ingelheim Investigational Site
Bangkok, Thailand, Thailand
Recruiting
1276.1.66003 Boehringer Ingelheim Investigational Site
Bangkok, Thailand, Thailand
Recruiting
1276.1.66002 Boehringer Ingelheim Investigational Site
Nakhon Ratchasima, Thailand
Recruiting
1276.1.90003 Boehringer Ingelheim Investigational Site
Ankara, Turkey
Recruiting
1276.1.90004 Boehringer Ingelheim Investigational Site
Antalya, Turkey
Recruiting
1276.1.90006 Boehringer Ingelheim Investigational Site
Denizli, Turkey
Recruiting
1276.1.90002 Boehringer Ingelheim Investigational Site
Erzurum, Turkey
Recruiting
1276.1.90005 Boehringer Ingelheim Investigational Site
Istanbul, Turkey
Recruiting
1276.1.90001 Boehringer Ingelheim Investigational Site
Izmir, Turkey
Recruiting
1276.1.44002 Boehringer Ingelheim Investigational Site
Bolton, United Kingdom
Recruiting
1276.1.44001 Boehringer Ingelheim Investigational Site
Bradford on Avon, United Kingdom
Recruiting
1276.1.44005 Boehringer Ingelheim Investigational Site
Chippenham, United Kingdom
Recruiting
1276.1.44006 Boehringer Ingelheim Investigational Site
Dagenham, United Kingdom
Recruiting
1276.1.44004 Boehringer Ingelheim Investigational Site
Doncaster, United Kingdom
Recruiting
1276.1.44008 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
Recruiting
1276.1.44003 Boehringer Ingelheim Investigational Site
Leeds, United Kingdom
Recruiting
1276.1.44007 Boehringer Ingelheim Investigational Site
Manchester, United Kingdom
Recruiting
1276.1.44011 Boehringer Ingelheim Investigational Site
Mortimer, United Kingdom
Recruiting
1276.1.44009 Boehringer Ingelheim Investigational Site
Sandbach, United Kingdom
Recruiting